Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort studyDaniel K. Nomah, Bibiana Morell, Juliana Reyes‐Urueña et al.|The Lancet HIV|2021Cited by 110
Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohortJosep M. Llibre, Alexandra Montoliu, JM Miró et al.|HIV Medicine|2019Cited by 38
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping reviewJorge Palacio‐Vieira, Eva González‐Roca, Juliana Reyes‐Urueña et al.|BMC Public Health|2021Cited by 37
Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practiceMarta Álvarez, Luis Miguel Garcia Sousa, Paz Casas et al.|Journal of Antimicrobial Chemotherapy|2019Cited by 22
Persistence of Novel First-Line Antiretroviral Regimes in a Cohort of HIV-Positive Subjects, Coris 2008–2010Inmaculada Jarrín, Beatriz Hernández‐Novoa, Belén Alejos et al.|Antiviral Therapy|2012Cited by 21